- AMRI (AMRI +3.9%) acquires Oso Biopharmaceuticals Manufacturing LLC (OsoBio) for $110M cash. OsoBio is a contract manufacturer of injectable drug products, including sterile liquid, suspension and lyophilized formulations. President & CEO William S. Marth says, "The acquisition of OsoBio is highly complementary to our finished dose manufacturing business and is consistent with our strategy to be the preeminent supplier of custom and complex drug development services and products to the pharmaceutical industry."
- On a stand-alone basis, OsoBio's 2014 revenue is expected to be $58M - 60M and EBITDA between $9M - 10M.
From other sites
at CNBC.com (Jan 9, 2015)
at MarketWatch.com (Oct 14, 2014)
at CNBC.com (Aug 15, 2014)
at MarketWatch.com (Dec 23, 2011)
at MarketWatch.com (May 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs